S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
Combining PARP inhibitors with ADCs
Heather McArthur notes early data that ADCs plus PARP inhibitors might extend benefit beyond germline BRCA mutations.
Play episode from 03:38
Transcript
